| Name | Title | Contact Details |
|---|---|---|
Devon Sharp |
Associate General Counsel | Profile |
Grant Riedesel |
Head of Legal, Corporate Development | Profile |
Tim Stow |
Global Head of Ethics and Compliance | Profile |
Sean Griffin |
Vice President of Regulatory Affairs | Profile |
eDerm Systems is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The US Oncology Network is one of the nation’s largest networks of integrated, community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care. A physician-led organization, The US Oncology Network unites like-minded physicians and clinicians around a common vision of improving patient outcomes and quality of life. Leveraging healthcare information technology, shared best practices, evidence-based guidelines and quality measurements, physicians within The US Oncology Network are pioneering new ways to achieve this vision. The US Oncology Network is committed to strengthening patient access to integrated care in local communities across the nation, including collaboration with a variety of payers, hospitals and academic institutions. The US Oncology Network is supported by McKesson Specialty Health, a division of McKesson Corporation focused on empowering a vibrant and sustainable community patient care delivery system.
Orahealth USA is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Behavioral Healthcare Options is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Repertoire Immune Medicines is working to unleash the remarkable power of the human immune system to prevent, treat or cure cancer, autoimmune conditions, and infectious diseases. Repertoire scientists created and developed a suite of technologies for its DECODE discovery and DEPLOY product platforms that allow in-depth characterization of the immune synapse and the ability to rationally design, and clinically develop, multi-clonal immune medicines. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15.